Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 24, Issue 2, Pages 221-231Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2022.2155047
Keywords
Behcet's syndrome; biologics; immunosuppressives; management; small molecules; treatment
Categories
Ask authors/readers for more resources
IntroductionBehcet's syndrome (BS) has a heterogeneous clinical phenotype, and its clinical manifestations may respond differently to drugs commonly used to treat BS. The type, dose, and duration of immunomodulatory, immunosuppressive, and biologic agents should be tailored individually.Areas coveredWe reviewed the literature for articles on BS management that were published until June 2022 and summarized the management options in BS for each type of organ involvement. We aimed to cover all currently available pharmacological agents used in BS, as well as surgical and interventional options, focusing on recent evidence.Expert opinionThe management aims in BS are to preserve function and quality of life and to avoid damage. The choice of treatment modalities depends on the organs that are actively involved, the severity of that involvement, and prognostic factors. A treat-to-attack strategy would help improve long-term outcomes in BS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available